Invesco Nasdaq Biotechnology ETF
$33.43−0.81 (−2.38%)
- 0.19%
- $112M
- +37.5%
- 1.14%
- 0M sh
- $34.57
- low $25.00high $36.84
The ETF.net IBBQ Grade
A
Score 77 out of 100
- 2 of 17
Score 77 of 100 falls in the A band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.A100 out of 100Rank 1 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.A84 out of 100Rank 4 of 9Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.A72 out of 100Rank 3 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.C46 out of 100Rank 10 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.B62 out of 100Rank 8 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.D39 out of 100Rank 14 of 17
Our read on IBBQ
AThe broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.
The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.
Why people hold it
- At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
- Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
- Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
- Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.
Worth knowing
- Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
- One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
- Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.
IBBQ Holdings
- Stocks
- 250
- 46%
- GILD
Sectors
- Health Care100.0%
- Financials0.0%
Geography
- United States88.73%
- United Kingdom2.34%
- Netherlands2.15%
- Ireland1.62%
- Switzerland1.24%
- Denmark1.19%
- France0.92%
- Germany0.75%
- 1.05%
IBBQ Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.
IBBQ$13,745
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IBBQ |
|---|---|
| Year to date | +21.7% |
| 1 month | 0.0% |
| 3 months | +4.2% |
| 1 year | +37.5% |
| 3 years | +21.7% |
| 5 years | +8.0% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IBBQ |
|---|---|---|
| 2026 YTD | +21.7% | |
| 2025 | +33.3% | |
| 2024 | −0.6% | |
| 2023 | +4.7% | |
| 2022 | −10.4% | |
| 2021 | −6.7% |
IBBQ in the news
IBBQ Dividends
- 1.14%
- $0.39
- $0.23 per share
- Quarterly
Distribution history
IBBQ Risk
- 17.5%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.99
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −34.8%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.61
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IBBQ Cost
0.19%
IBBQ0.19%
- The middle half of Biotech & Genomics funds
- Median 0.47%
No Biotech & Genomics fund charges less.
Other funds in Biotech & Genomics
- AXBIState Street SPDR S&P Biotech ETFExpense ratio 0.35%1 year return +44.8%
- ABBPVirtus Biotech ETFExpense ratio 0.34%1 year return +47.9%
- AIBBiShares Biotechnology ETFExpense ratio 0.44%1 year return +36.5%
- BBBHVanEck Biotech ETFExpense ratio 0.35%1 year return +39.7%
- BFBTFirst Trust NYSE Arca Biotechnology Index FundExpense ratio 0.55%1 year return +44.7%